V J Ferrans

11.4k citations

140 papers · 9.1k indexed · 2 hit papers · h-index 52

Impact in

Cardiology and Cardiovascular Medicine top 0.5%
- Chemotherapy-induced cardiotoxicity and mitigation
- Cardiomyopathy and Myosin Studies
- Cardiac Valve Diseases and Treatments
Pulmonary and Respiratory Medicine top 0.5%
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Neonatal Respiratory Health Research
- Inhalation and Respiratory Drug Delivery
- Medical Imaging and Pathology Studies

Papers in

Cardiology and Cardiovascular Medicine 64
- Chemotherapy-induced cardiotoxicity and mitigation 23
- Cardiomyopathy and Myosin Studies 12
- Cardiac Valve Diseases and Treatments 12
- Cardiovascular Function and Risk Factors 9
Immunology and Allergy 9
- Cell Adhesion Molecules Research 9

Co-authors: Ronald G. Crystal Oichi Kawanami Gary W. Hunninghake Erik Herman William C. Roberts James E. Gadek Zu‐Xi Yu John F. Van Vleet
Journals: Circulation (11 papers)Journal of Molecular and Cellular Cardiology (9 papers)Journal of Clinical Investigation (5 papers)Cancer Chemotherapy and Pharmacology (3 papers)Toxicology (2 papers)
Partner nations: United States Japan United Kingdom

In The Last Decade

V J Ferrans

140 papers receiving 8.5k citations

Hit Papers

align trajectories log scale

Reactive oxygen species are downstream mediators of p53-dependent apoptosis. 1996 · 506 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

1996 Proceedings of the National Academy of Sciences
1979 PubMed

Peers

Countries citing papers authored by V J Ferrans

Since Specialization

Citations

This map shows the geographic impact of V J Ferrans's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by V J Ferrans with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites V J Ferrans more than expected).

Fields of papers citing papers by V J Ferrans

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by V J Ferrans. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by V J Ferrans. The network helps show where V J Ferrans may publish in the future.

Co-authorship network

The 25 scholars most cited alongside V J Ferrans, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with V J Ferrans Line = papers co-authored together V J Ferrans links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Chemical, Biological and Clinical Aspects of Dexrazoxane and Other Bisdioxopiperazines Current Medicinal Chemistry ·Brian B. Hasinoff, K. Hellmann, Erik Herman, V J Ferrans	1998	131
2	Protection from reoxygenation injury by inhibition of rac1. Journal of Clinical Investigation ·Kyo Sang Kim, Kazuyo Takeda, R. A. MacCarthy, J.B. Pracyk, Kazuo Tanaka, Yingying Zhou, Zu‐Xi Yu, V J Ferrans, Jesus L. Lastra, Imre Kovesdi, Kaikobad Irani, Pascal J. Goldschmidt‐Clermont, Toren Finkel	1998	129
3	Differential expression of matrix metallproteinases in coronary thrombosis: plaque rupture and erosion Journal of the American College of Cardiology ·Frank D. Kolodgie, Sarwatullah Siddiqui, Andrew Farb, Allen Burke, Koji Horiba, V J Ferrans, William G. Stetler‐Stevenson, R Virmani	1998	3
4	Comparison of the protective effects against chronic doxorubicin cardiotoxicity and the rates of iron (III) displacement reactions of ICRF-187 and other bisdiketopiperazines Cancer Chemotherapy and Pharmacology ·Erik Herman, Shailendra Kr Maurya, Brian B. Hasinoff, Douglas P. Chadwick, J. Clark, V J Ferrans	1997	23
5	Activated Neutrophils Secrete Stored Alpha 1-Antitrypsin American Journal of Respiratory and Critical Care Medicine ·Paavo Pääkkö, Martha Kirby, R M du Bois, A Gillissen, V J Ferrans, R G Crystal	1996	42
6	Alveolar Fibrosis and Capillary Alteration in Experimental Pulmonary Silicosis in Rats American Journal of Respiratory and Critical Care Medicine ·Oichi Kawanami, Elias Leutgeb, Hiroshi Mochimaru, D.W. Lee, Shoji Kudoh, Hisashi Ohkuni, L. Morka, V J Ferrans	1995	36
7	3,5,3′-Triiodo-L-Thyronine Induces Cardiac Myocyte Differentiation but Not Neuronal Differentiation in P19 Teratocarcinoma Cells in a Dose-Dependent Manner Biochemical and Biophysical Research Communications ·E. René Rodríguez, خلود بنت حمدان الخاطرية, W.B. Matthews, Zu‐Xi Yu, V J Ferrans, Joseph E. Parrillo	1994	13
8	ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. Journal of Clinical Oncology ·James L. Speyer, Achnia Azla, Anne Zeleniuch‐Jacquotte, J Wernz, Mariano Rey, Joseph J. Sanger, E Douglas Kramer, V J Ferrans, Howard S. Höchster, Marleen Meyers	1992	263
9	Effect of ICRF-187 on the pulmonary damage induced by hyperoxia in the rat Toxicology ·Yoko Fukuda, Erik Herman, V J Ferrans	1992	11
10	Structural changes in implanted cardiac valvular bioprostheses constructed of glycerol-treated human dura mater European Journal of Cardio-Thoracic Surgery ·V J Ferrans, José Milei, Mehmet Yitmen, Rubén Storino	1991	8
11	Antitumor Activity of Liposome-Encapsulated Doxorubicin in Advanced Breast Cancer: Phase II Study JNCI Journal of the National Cancer Institute ·Joseph Treat, Andrew Greenspan, Deborah Forst, Julian Sanchez, V J Ferrans, R. F. CHANG, Paul V. Woolley, A Rahman	1990	99
12	Cardiac morphologic and functional changes induced by epirubicin chemotherapy. Journal of Clinical Oncology ·Michelle B. Raganit, V J Ferrans, Thanakarn Nasri, Ewa Piętka, Firew Tiruneh Tiyare, 윤복연, David W. Alling, Steve Banks, F. Julbe	1989	37
13	Morphologie Characterization of Alveolar Macrophages from Subjects with Occupational Exposure to Inorganic Particles American Review of Respiratory Disease ·Tamiko Takemura, William N. Rom, V J Ferrans, Ronald G. Crystal	1989	47
14	Countercurrent Chromatography of an Anti-trypanosomal Factor from Pseudomonas Fluorescens Journal of Liquid Chromatography ·Josip Lipovac, Yoichiro Ito, B. J. Kopp, V J Ferrans	1988	1
15	Demonstration by in situ hybridization of dissimilar IL-1 beta gene expression in human alveolar macrophages and blood monocytes in response to lipopolysaccharide. The Journal of Immunology ·Jean‐François Bernaudin, Kiyomi Yamauchi, Mark D. Wewers, Michael J. Tocci, V J Ferrans, R G Crystal	1988	61
16	Dendritic cells with antigen-presenting capability reside in airway epithelium, lung parenchyma, and visceral pleura. The Journal of Experimental Medicine ·K Sertl, Tamiko Takemura, Erwin Tschachler, V J Ferrans, Michael Kaliner, Ethan M. Shevach	1986	282
17	Collagen concentration and rates of synthesis in idiopathic pulmonary fibrosis. PubMed ·Jack D. Fulmer, Robert S. Bienkowski, Morton J. Cowan, Hugo Ricardo Gómez Ruiz, Kevin M. Bradley, V J Ferrans, W C Roberts, Ronald G. Crystal	1980	77
18	Cardiac lesions induced by chemicals. Environmental Health Perspectives ·Tibor Balázs, V J Ferrans	1978	20
19	Ultrastructural features of degenerated cardiac muscle cells in patients with cardiac hypertrophy. PubMed Central ·Barry J. Maron, V J Ferrans, William C. Roberts	1975	171
20	Endomyocardial biopsy: Its clinical application The American Journal of Cardiology ·Delia Sundari, V J Ferrans, Tazewell Banks, William C. Roberts	1974	1

About V J Ferrans

V J Ferrans is a scholar working on Cardiology and Cardiovascular Medicine, Immunology and Allergy, Pulmonary and Respiratory Medicine, Rheumatology and Oncology, having authored 140 papers that have together received 9.1k indexed citations. Recurring topics across this work include Chemotherapy-induced cardiotoxicity and mitigation (23 papers), Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (16 papers), Cardiomyopathy and Myosin Studies (12 papers), Cardiac Valve Diseases and Treatments (12 papers), Neonatal Respiratory Health Research (12 papers), Cancer Treatment and Pharmacology (11 papers), Cardiovascular Function and Risk Factors (9 papers) and Cell Adhesion Molecules Research (9 papers). The work is most often cited by research in Cardiology and Cardiovascular Medicine (2.8k citations), Pulmonary and Respiratory Medicine (2.9k citations), Immunology (1.1k citations), Oncology (1.3k citations) and Immunology and Allergy (282 citations). V J Ferrans has collaborated with scholars based in United States, Japan and United Kingdom. Frequent co-authors include Ronald G. Crystal, Oichi Kawanami, Gary W. Hunninghake, Erik Herman, William C. Roberts, James E. Gadek, Zu‐Xi Yu, John F. Van Vleet, Toren Finkel and Thomas M. Johnson. Their work appears in journals such as Circulation, Journal of Molecular and Cellular Cardiology, Journal of Clinical Investigation, Cancer Chemotherapy and Pharmacology and Toxicology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact